6733.TWO
Price:
$38.2
Market Cap:
$4.75B
BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.
Industry
Biotechnology
IPO Date
2019-06-18
Stock Exchange
TWO
Ticker
6733.TWO
According to BioGend Therapeutics Co., Ltd.’s latest financial reports and current stock price. The company's current ROE is -15.67%. This represents a change of 300.55% compared to the average of -3.91% of the last 4 quarters.
The mean historical ROE of BioGend Therapeutics Co., Ltd. over the last ten years is -20.17%. The current -15.67% ROE has changed -22.32% with respect to the historical average. Over the past ten years (40 quarters), 6733.TWO's ROE was at its highest in in the March 2024 quarter at -1.18%. The ROE was at its lowest in in the December 2022 quarter at -7.59%.
Average
-20.17%
Median
-18.64%
Minimum
-27.65%
Maximum
-14.24%
Discovering the peaks and valleys of BioGend Therapeutics Co., Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 68.19%
Maximum Annual ROE = -14.24%
Minimum Annual Increase = -36.69%
Minimum Annual ROE = -27.65%
| Year | ROE | Change |
|---|---|---|
| 2024 | -14.24% | -14.26% |
| 2023 | -16.61% | -36.69% |
| 2022 | -26.24% | 68.19% |
| 2021 | -15.60% | -24.49% |
| 2020 | -20.66% | -25.25% |
The current ROE of BioGend Therapeutics Co., Ltd. (6733.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-19.03%
5-year avg
-18.67%
10-year avg
-20.17%
BioGend Therapeutics Co., Ltd.’s ROE is less than Savior Lifetec Corporation (12.67%), greater than UnicoCell Biomed Co., Ltd. (-12.58%), less than Panion & Bf Biotech Inc. (6.83%), greater than AnnJi (-54.10%), greater than Formosa Pharmaceuticals, Inc. (-3.92%), greater than Medigen Biotechnology Corp. (-3.79%), greater than TaiGen Biopharmaceuticals Holdings Limited (-22.99%), less than Sinphar Pharmaceutical Co.,Ltd. (9.51%), greater than Pharmosa Biopharm Inc. (-15.24%), greater than Senhwa Biosciences, Inc. (-27.83%),
| Company | ROE | Market cap |
|---|---|---|
| 12.67% | $5.65B | |
| -12.58% | $4.81B | |
| 6.83% | $5.72B | |
| -54.10% | $4.33B | |
| -3.92% | $4.23B | |
| -3.79% | $4.26B | |
| -22.99% | $7.94B | |
| 9.51% | $5.83B | |
| -15.24% | $6.92B | |
| -27.83% | $3.58B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioGend Therapeutics Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioGend Therapeutics Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is BioGend Therapeutics Co., Ltd.'s ROE?
How is the ROE calculated for BioGend Therapeutics Co., Ltd. (6733.TWO)?
What is the highest ROE for BioGend Therapeutics Co., Ltd. (6733.TWO)?
What is the 3-year average ROE for BioGend Therapeutics Co., Ltd. (6733.TWO)?
What is the 5-year average ROE for BioGend Therapeutics Co., Ltd. (6733.TWO)?
How does the current ROE for BioGend Therapeutics Co., Ltd. (6733.TWO) compare to its historical average?